Human Cd3 Antibody for Advanced Research - Explore Quality Options

Discover the cutting-edge Human CD3 Antibody from Alpha Lifetech Incorporation, a leading provider of high-quality life science research products. Our Human CD3 Antibody is specifically designed for the precise detection and analysis of CD3, a crucial Protein found on the surface of T-lymphocytes. This monoclonal antibody has been rigorously tested and validated for its specificity and sensitivity, ensuring reliable and reproducible results for your research needs, The Human CD3 Antibody is suitable for a wide range of applications, including flow cytometry, immunohistochemistry, and immunoprecipitation, making it a versatile tool for studying immune responses, cell signaling, and autoimmune diseases. With its exceptional performance and consistency, our Human CD3 Antibody is an essential addition to any immunology or cell biology research laboratory, Trust Alpha Lifetech Incorporation to provide you with the highest quality Human CD3 Antibody for your research endeavors. Contact us today to learn more about how our innovative products can advance your scientific pursuits

Hot Selling Product

ADT1005-Abciximab Biosimilar: (ITGA2B_ITGB3)- Research Grade

ALP64515-Recombinant Human CD73 Protein, Fc Tag

ALP64536-Recombinant Cynomolgus Monkey TNFSF18/GITRL Protein, His Tag

ALP64546-Recombinant Human CD273/PD-L2/B7-DC Protein, His Tag, Avi Tag

ALP64550-Recombinant Human ILT3/CD85k/LILRB4 Protein, His Tag

ADT1454-Odronextamab Biosimilar-Anti-CD3/CD20 mAb-Research Grade

Best Options For Human Cd3 Antibody Ahead of the Curve From Concept to Delivery

At Alpha Lifetech Inc., we are committed to pushing the boundaries of science and innovation, particularly in the field of antibody development. Our focus on producing high-quality human CD3 antibodies places us at the forefront of immunology research and therapeutic applications. With nearly a decade of experience in membrane protein production and monoclonal development, our team of seasoned scientists understands the critical role that high-quality reagents play in the success of research and clinical applications. Our human CD3 antibodies are ideal for various applications, from basic research to advanced therapeutic solutions. Each antibody is developed through rigorous quality control processes and validated for optimal performance in various assays. We take pride in our extensive inventory of over 10,000 membrane protein reagents, cytokines, and drug target antibodies, ensuring that we can meet the diverse needs of researchers and clinicians around the globe. As we continue to evolve and expand our product offerings, Alpha Lifetech Inc. remains dedicated to providing not only exceptional products but also unparalleled customer support. We are here to assist you every step of the way, from the initial inquiry to timely delivery. Partner with us and stay ahead of the curve in your research and development efforts with our leading-edge human CD3 antibodies. Transform your scientific concepts into impactful discoveries with Alpha Lifetech Inc. as your trusted ally.

Best Options For Human Cd3 Antibody Ahead of the Curve From Concept to Delivery

Antibody Name	Type	Target	Application	Status	Delivery Timeline
Anti-CD3 Monoclonal Antibody A	IgG1	CD3	IM & IV Administration	Clinical Trial Phase II	6 months
Anti-CD3 Monoclonal Antibody B	IgG2a	CD3	Subcutaneous	Preclinical Stage	8 months
Anti-CD3 Monoclonal Antibody C	IgG1κ	CD3	IV Infusion	Clinical Trial Phase I	4 months
Anti-CD3 Monoclonal Antibody D	IgG2	CD3	Combined Therapy	Development Stage	12 months

Trends in Human CD3 Antibody Research Over the Years

The field of human CD3 antibody research has experienced significant growth over the past several years, as reflected in the increasing number of research publications. From 150 publications in 2018, the volume of research climbed steadily to reach an impressive 600 publications in 2023. This upward trend indicates not only the rising interest in CD3 antibodies but also their potential applications in therapeutic areas, particularly in immunology and oncology.

This surge in research can be attributed to numerous factors, including advancements in antibody engineering techniques, growing investments in biotechnology, and a deeper understanding of the immune system's role in disease. The ability of CD3 antibodies to modulate T cell responses offers promising therapeutic avenues for treating conditions such as cancer and autoimmune diseases.

As researchers continue to explore novel applications and improve existing methodologies, we can anticipate even more innovative breakthroughs in the coming years. This ongoing progress underscores the relevance of human CD3 antibodies in contemporary biomedical research and highlights the importance of staying ahead in this rapidly evolving field.